Sermorelin Evidence Guide
Sermorelin has legitimate historical approval and human GH-stimulation data, but no currently marketed FDA-approved product and no validated anti-aging indication. Tesamorelin has the stronger current regulatory record; CJC-1295 is not an approved substitute.
Our Take
Sermorelin has legitimate historical approval and human GH-stimulation data, but no currently marketed FDA-approved product and no validated anti-aging indication. Tesamorelin has the stronger current regulatory record; CJC-1295 is not an approved substitute.
- Evidence context
- Historical pediatric GH-deficiency evidence and GHRH-axis research
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: No current FDA-approved product or general outpatient protocol
Benefits and Evidence
- Growth Hormone Stimulation: Level B, includes human evidence - Well-documented ability to stimulate GH release in both children and adults. Less potent than exogenous GH but produces more physiological GH patterns.
- Body Composition (Adults): Level C, includes human evidence - Limited evidence for improved lean body mass and reduced body fat in GH-deficient adults. Effects are gradual and modest compared to direct GH therapy.
- Sleep Quality: Level C, includes human evidence - Some evidence of improved sleep quality, particularly deep sleep stages, consistent with the role of GH in sleep regulation.
Side Effects and Warnings
- Injection site reactions (redness, swelling)
- Facial flushing
- Headache
- Dizziness
- Sleepiness
- Previously FDA-approved but discontinued (for commercial, not safety reasons)
- May not be effective in severe pituitary damage
- Monitor for excessive GH/IGF-1 elevation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 100-300 mcg - Once daily at bedtime - Bedtime dosing optimizes natural nocturnal GH pulse. Take on empty stomach.
- <strong>Subcutaneous (combined)</strong> - 100-200 mcg - Once or twice daily - Often combined with ipamorelin or GHRP-6 for synergistic effects.
Mechanism of Action
Sermorelin stimulates GH through the natural GHRH pathway: 1. GHRH receptor activation: Directly binds pituitary GHRH receptors to stimulate GH synthesis and secretion. 2. Physiological GH release: Promotes natural pulsatile GH release pattern, unlike exogenous GH which creates non-physiological levels. 3. Negative feedback preserved: Does not override the body's negative feedback mechanisms, reducing risk of supraphysiological GH levels. 4. Pituitary health: May support pituitary somatotroph health and function long-term. 5. IGF-1 normalization: Gradually normalizes IGF-1 levels through sustained physiological GH stimulation.
Legal Status
Geref previously held FDA approval for pediatric growth hormone deficiency and diagnostic use. Drugs@FDA lists the sermorelin products as discontinued and not withdrawn for safety or effectiveness reasons. Compounded sermorelin products are not FDA-approved and are not reviewed like an approved drug before marketing.
Primary Sources
Quick Answers
Where is the strongest evidence for Sermorelin?
Sermorelin has legitimate historical approval and human GH-stimulation data, but no currently marketed FDA-approved product and no validated anti-aging indication. Tesamorelin has the stronger current regulatory record; CJC-1295 is not an approved substitute. Evidence context: Historical pediatric GH-deficiency evidence and GHRH-axis research.
What are the main side effects of Sermorelin?
Sermorelin side effects and warning signals include Injection site reactions (redness, swelling), Facial flushing, Headache, Dizziness, and Sleepiness.
What evidence level is Sermorelin?
Sermorelin is rated Level B; the listed research status is Historical FDA Approval.